Skip to main content
Top
Published in: Journal of Hematology & Oncology 1/2015

Open Access 01-12-2015 | Research

Hematology research output from Chinese authors and other countries: a 10-year survey of the literature

Authors: Lei Zhang, Xin Ye, Yi Sun, An-mei Deng, Bao-hua Qian

Published in: Journal of Hematology & Oncology | Issue 1/2015

Login to get access

Abstract

Background

Hematologic disease affects people of all ages worldwide. In the past decade, researchers have made great progress in the field of hematology. In the present study we compared the hematology research output from China and other countries (USA, Germany, UK, Japan and South Korea) over the past 10 years and 5 years.

Methods

The related articles were extracted based on the PubMed database. We recorded the number of publications, clinical trials, randomized controlled trials, meta-analyses, case reports, reviews, citations, impact factors, articles in the top 10 journals and most published journals to assess the quantity and quality of research output in each region.

Results

A total of 120,641 hematology-related articles were published from 2004 to 2013. The USA accounted for 27.13% (32,732/120,641) of the publications, followed by Germany (7,479/120,641; 6.20%), Japan (6,347/120,641; 5.26%), the UK (5,453/120,641; 4.52%), China (2,924/120,641; 2.42%) and South Korea (1,413/120,641; 1.17%). The ranking for cumulative impact factors was as follows: USA; Germany; UK; Japan; China and South Korea. The median impact factors in the UK, USA, and Germany were higher than Japan, South Korea, and China. Interestingly, the median impact factors in the three Asia countries were similar both in 2004–2013 and 2009–2013. The UK had the highest percentage of publications in the top 25% of journals, while China lagged behind and ranked last. When comparing the number of articles in the top 10 journals, the results were similar to the IF findings. Germany had the highest number of average citations, while China had the lowest number of average citation. The status of hematology research output from the 6 countries in 2009–2013 had little difference from 2004–2013.

Conclusions

Thus, the USA has had a dominant role in hematologic research in the past 10 years. Overall, the quality of publications in European countries was better than Asia countries. Although China has made considerable progress in hematology research, the quality of research needs improvement.
Appendix
Available only for authorised users
Literature
1.
go back to reference World Health Organization. World health statistics. 2014. World Health Organization. World health statistics. 2014.
2.
go back to reference Yang G, Wang Y, Zeng Y, Gao GF, Liang X, Zhou M, et al. Rapid health transition in china, 1990–2010: Findings from the global burden of disease study 2010. Lancet. 2010;381:1987–2015.CrossRef Yang G, Wang Y, Zeng Y, Gao GF, Liang X, Zhou M, et al. Rapid health transition in china, 1990–2010: Findings from the global burden of disease study 2010. Lancet. 2010;381:1987–2015.CrossRef
5.
go back to reference Rethlefsen ML, Murad MH, Livingston EH. Engaging medical librarians to improve the quality of review articles. Jama. 2014;312:999–1000.CrossRefPubMed Rethlefsen ML, Murad MH, Livingston EH. Engaging medical librarians to improve the quality of review articles. Jama. 2014;312:999–1000.CrossRefPubMed
10.
go back to reference Chen S, Pan Y, Yao Q, Yao L, Liu Z, Xiang L. Publication pressure on chinese doctors–another view. Lancet. 2014;384:956.CrossRefPubMed Chen S, Pan Y, Yao Q, Yao L, Liu Z, Xiang L. Publication pressure on chinese doctors–another view. Lancet. 2014;384:956.CrossRefPubMed
11.
Metadata
Title
Hematology research output from Chinese authors and other countries: a 10-year survey of the literature
Authors
Lei Zhang
Xin Ye
Yi Sun
An-mei Deng
Bao-hua Qian
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2015
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/s13045-014-0103-3

Other articles of this Issue 1/2015

Journal of Hematology & Oncology 1/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine